dc.contributor.advisor | Kabir, Eva Rahman | |
dc.contributor.author | Roja, Mashwiyat Samrin | |
dc.date.accessioned | 2024-06-09T06:02:36Z | |
dc.date.available | 2024-06-09T06:02:36Z | |
dc.date.copyright | ©2022 | |
dc.date.issued | 2023-10 | |
dc.identifier.other | ID: 19346046 | |
dc.identifier.uri | http://hdl.handle.net/10361/23250 | |
dc.description | This thesis is submitted in partial fulfillment of the requirements for the degree of Bachelor of Pharmacy, 2023. | en_US |
dc.description | Cataloged from the PDF version of thesis. | |
dc.description | Includes bibliographical references (pages 27-34). | |
dc.description.abstract | The increasing prevalence of BRAFV600E mutated cancers has led to the search and
development of targeted therapies against BRAF mutation. Multiple cancers, including
colorectal cancer (CRC), have been linked to this mutation. While the currently available CRC
drugs have shown initial promise, long-term use of these drugs could lead to the emergence of
resistant CRC cells; therefore, drug repurposing provides a powerful strategy to increase the
existing drug pool. This docking-based study’s aim was to find the possible compounds that
could inhibit the BRAF protein and treat BRAFV600E mutated CRC. Three classes of drugs antihypertensive,
anti-cholesterol and anti-diabetic drugs were explored. Molecular docking,
followed by superimposition, analyzing protein-ligand interactions and comparison of their
pharmacokinetic properties were done. The anti-hypertensive drug, Verapamil showed
promising results as it demonstrated good binding affinity and interaction with the target
protein. However, further in vitro studies and biological assays should be performed to
elucidate Verapamil’s efficacy. | en_US |
dc.description.statementofresponsibility | Mashwiyat Samrin Roja | |
dc.format.extent | 47 pages | |
dc.language.iso | en | en_US |
dc.publisher | Brac University | en_US |
dc.rights | Brac University theses are protected by copyright. They may be viewed from this source for any purpose, but reproduction or distribution in any format is prohibited without written permission. | |
dc.subject | BRAFV600E | en_US |
dc.subject | CRC | en_US |
dc.subject | Colorectal cancer | en_US |
dc.subject | Cancer | en_US |
dc.subject.lcsh | Rectum--Cancer | |
dc.subject.lcsh | Colon (Anatomy)--Cancer | |
dc.subject.lcsh | Cancer--Treatment | |
dc.title | Targeting BRAFV600E in the treatment of CRC | en_US |
dc.type | Thesis | en_US |
dc.contributor.department | School of Pharmacy, Brac University | |
dc.description.degree | B. Pharmacy | |